&lt;p&gt;Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy&lt;/p&gt;

Ni, Jia Yan; Sun, Hong; Luo, Jiang; Jiang, Xiong Ying; Chen, Dong; Wang, Weidong; Chen, Yao Ting; Huang, Jin; Xu, Lin

doi:10.2147/cmar.s224532

Cited by 8 publications

(8 citation statements)

References 46 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, as a palliative treatment, TACE cannot eliminate viable tumor cells, which may result in the failure of TACE due to local tumor recurrence and distant metastasis [120,170]. For the development and further applications of the TACE, supplemental therapeutic mechanisms, including magnetic induction hyperthermia (MIH) [145,171], microwave ablation (MWA) [172,173], high-intensity focused ultrasound (HIFU) thermotherapy [120,170,174], photothermal therapy (PTT) [175,176], and radiofrequency ablation (RFA) [177,178], etc., have been introduced to enhance the therapeutic effects. Extensive clinical studies have confirmed improved outcomes through combination therapy of TACE with interventional thermal/nonthermal ablation modalities [14,[179][180][181].…”

Section: Microspheres For Arterial Embolization Hyperthermiamentioning

confidence: 99%

Bench-to-bedside development of multifunctional flexible embolic agents

Wang¹,

Rao²

2023

Theranostics

View full text Add to dashboard Cite

Transarterial chemoembolization (TACE) has been demonstrated to provide a survival benefit for patients with unresectable hepatocellular carcinoma (HCC). However, conventional TACE still faces limitations associated with complications, side effects, unsatisfactory tumor responses, repeated treatment, and narrow indications. For further improvement of TACE, additional beneficial functions such as degradability, drug-loading and releasing properties, detectability, targetability, and multiple therapeutic modalities were introduced. The purpose here is to provide a comprehensive overview of current and emerging particulate embolization technology with respect to materials. Therefore, this review systematically identified and described typical features, various functions, and practical applications of recently emerging micro/nano materials as particulate embolic agents for TACE. Besides, new insights into the liquid metals-based multifunctional and flexible embolic agents were highlighted. The current development routes and future outlooks of these micro/nano embolic materials were also presented to promote advancement in the field.

show abstract

Section: Microspheres For Arterial Embolization Hyperthermiamentioning

confidence: 99%

Bench-to-bedside development of multifunctional flexible embolic agents

Wang¹,

Rao²

2023

Theranostics

View full text Add to dashboard Cite

show abstract

“…Palliative ablation therapy for advanced HCC is currently under investigation. Nevertheless, combining TACE ablation and sorafenib has shown longer survival for patients with BCLC stage C [51].…”

Section: Therapies For Advanced Hccmentioning

confidence: 99%

Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements

Sun

Wen

et al. 2022

Liver Cancer

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and causes many cancer-related deaths worldwide; in China it is the second most prevalent cause of cancer deaths. Most patients are diagnosed clinically with advanced stage disease. Summary: For more than a decade, sorafenib, a small molecular weight tyrosine kinase-inhibitor (SMW TKI) was the only molecular targeted drug available with a survival benefit for the treatment of advanced HCC. With the development of novel TKIs and immune checkpoint inhibitors (ICIs) for advanced HCC, the management of patients has been greatly improved. However, though angiogenic-based targeted therapy remains the backbone for the systemic treatment of HCC, to date no Chinese guidelines for novel molecular targeted therapies to treat advanced HCC have been established. Our interdisciplinary panel on the treatment of advanced HCC comprising hepatologists, hepatobiliary surgeons, oncologists，radiologists，pathologists, orthopedic surgeons, traditional Chinese medicine physicians and interventional radiologists have reviewed the literature in order to develop updated treatment regimens. Key Messages: Panel consensus statements for the appropriate use of new molecular targeted drugs including doses, combination therapies, adverse reaction management as well as efficacy evaluation and predictions for treatment of advanced HCC with evidence levels based on published data are presented, thereby providing an overview of molecular targeted therapies for healthcare professionals.

show abstract

“…The detailed characteristics of included relevant studies for this network meta-analysis were described in Table 1. which contained 8 RCTs (6,9-23) and 20 retrospective studies (10,(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41).…”

Section: Study Characteristics and Quality Assessmentmentioning

confidence: 99%

Identifying optimal therapies in patients with advanced hepatocellular carcinoma: a systematic review and network meta-analysis

Yang¹,

Tong²,

Yang³

et al. 2022

Transl Gastroenterol Hepatol

View full text Add to dashboard Cite

Background: Recently, there is an increasingly literatures have been reported on optimal therapies in patients with advanced hepatocellular carcinoma (HCC) and many therapeutic modalities have been proposed to improve survival rate. However, the results are not consistent due to different research protocols, small sample sizes and different study endpoints and there is no standard treatment protocol has been defined. Therefore, it is very important to explore the optimal bonding mode and to evaluate the efficacy and safety of the optimal sequential therapy for those patients.Methods: We searched available databases through January 2020 for relevant studies. The main outcome measure was 1-year overall survival (OS) and overall response rate (ORR); the secondary outcome measure was a composite of toxic effects retrieved grade 3 or 4 adverse events (AEs) from all included studies. Statistical analyses were conducted using STATA version 15 and GeMTC package in the R statistical software.Results: After a detailed review, 8 randomized controlled trials (RCTs) and 20 retrospective studies involving 3,675 advanced HCC patients were included for network meta-analysis. Indirect comparisons showed that hepatic arterial infusion chemotherapy (HAIC) plus radiofrequency ablation (RFA) was highest probability of obtaining the best OS rate of 1 year [surface under the cumulative ranking (SUCRA), 0.95] and ORR (SUCRA, 0.86) when compared with other potential optimal therapies and which had ranked the first in all treatment regimens, followed by HAIC (SUCRA, 0.75). Direct and indirect comparison of 1-year OS and ORR with all treatment regimens each other showed that for all treatment regimens, patients showed significant clinical benefit when compared with transcatheter arterial chemoembolization (TACE) or sorafenib alone. However, the incidence of treatment-related AEs of grade 3 or 4 occurred in patients who have received targeted drug sorafenib therapy (SUCRA, 0.51) compared with other interested regimens.Conclusions: HAIC may be a valuable therapeutic strategy for advanced HCC patients to prevent recurrence and metastasis after RFA, as well as in improving patient prognosis and quality of life. Meanwhile, HAIC combined with RFA is a safe and effective treatment in patients with advanced HCC, and this combination therapy can significantly prolong 1-year survival rate when compared with other optimal sequential therapies.Trial registration: This study is registered with PROSPERO, number CRD42020176149.

show abstract

<p>Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy</p>

Cited by 8 publications

References 46 publications

Bench-to-bedside development of multifunctional flexible embolic agents

Bench-to-bedside development of multifunctional flexible embolic agents

Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements

Identifying optimal therapies in patients with advanced hepatocellular carcinoma: a systematic review and network meta-analysis

Contact Info

Product

Resources

About